Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-04-18
2011-10-18
Li, Q. Janice (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S455000, C435S461000
Reexamination Certificate
active
08039445
ABSTRACT:
The present invention relates, generally, to improved methods of delivering a biologically active agent, in particular a therapeutic or prophylactic nucleic acid, to the ocular sphere of a subject comprising administering said agent to the ciliary body tissue(s) or cells and/or to the extra-ocular muscle tissue or cells. More particularly, the invention relates to devices, their uses, notably in gene therapy, and to methods for treating pathologies of the ocular sphere by specific ciliary body tissue(s) or cells and/or extra-ocular muscle or cells administration of a therapeutic product and transfer thereof into the ocular tissue to be treated. This invention also relates to pharmaceutical compositions comprising the product in a form suitable for ciliary body tissue(s) or cells and/or extra-ocular muscle or cells administration, their preparation and uses.
REFERENCES:
patent: 5944710 (1999-08-01), Dev et al.
patent: 6204251 (2001-03-01), Cuthbertson
patent: 0 927 560 (1999-07-01), None
patent: 1 452 203 (2004-09-01), None
Borrás et al. IOVS 2002;8:2513-8.
Borrás, Exp Eye Res 2003;76:643-52.
Mamiya et al. Exp Eye Res 2004;79:405-10.
Voigt et al. Biochem Biophy Res Comm 2002;295:336-41.
McLoon et al. IOVS 2003;44:3866-72.
Lemaitre et al. IOVS 2001;42:2022-30.
Scott, “Botulinum Toxin Injection into Extra Ocular Muscles as an Alternative to Strabismus Surgery”, XP002396760, Database Accession No. PREV198171054950, Abstract, Ophthalmology, 1980; 87: 1044-9.
Bloquel, et al., “Plasmid Electrotransfer of Eye Ciliary Muscle: Principles and Therapeutic Efficacy Using hTNF-α Soluble Receptor in Uveitis”, The FASEB Journal, express article 10,1096/fj.05-4737fje, Dec. 13, 2005.
Dezawa, et al., “Gene transfer into retinal ganglion cells by in vivo electroporation: a new approach”, Micron, vol. 33, p. 1-6, 2002.
Matsuda and Cepko, “Electroporation and RNA interference in the rodent retina in vivo and in vitro”, PNAS, vol. 101, No. 1, p. 16-22, Jan. 6, 2004.
Spencer, et al., “Herpes Simplex Virus-Mediated Gene Delivery to the Rodent Visual System”, Investigative Ophthalmology & Visual Science, vol. 41, No. 6, May 2000.
Behar-Cohen Francine
Benezra David
Bigey Pascal
Bloquel Carole
Scherman Daniel
Hunton & Williams LLP
INSERM (Institut National de la Sante et de la Recherche Medical
Li Q. Janice
LandOfFree
Methods and devices for delivering a therapeutic product to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and devices for delivering a therapeutic product to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and devices for delivering a therapeutic product to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4292981